索拉非尼联合塞来昔布对胆管癌细胞株SK-ChA-1增殖的影响  

Effect of sorafenib and celecoxib combination therapy on proliferation of the human cholangiocarcinoma cell line SK-ChA-1 in vitro

作　　者：万云燕[1] 李玲[2] 黄军利[3] 黄榕[3] 应可满[3] 陈强[4] 罗琪[5] 李文岗[1,3] 

机构地区：[1]福建医科大学福总临床医学院,福州350025 [2]湖北医药学院附属太和医院普外1科,湖北十堰442000 [3]解放军174医院,福建厦门361001 [4]厦门大学生命科学院,福建厦门361005 [5]厦门大学附属第一医院,福建厦门361001

出　　处：《临床肝胆病杂志》2013年第1期68-71,共4页Journal of Clinical Hepatology

基　　金：国家自然科学基金资助项目(81072014)

摘　　要：目的研究索拉非尼联合塞来昔布在体外对胆管癌细胞株SK-ChA-1增殖的影响。方法体外培养人胆管癌细胞株SK-ChA-1,通过MTT法检测索拉非尼单用或与塞来昔布联用时对胆管癌细胞株增殖的抑制作用,Western Blot分析索拉非尼单用或与塞来昔布联用时对胆管癌细胞株内多聚ADP核糖聚合酶(PARP)蛋白表达的影响。结果索拉非尼抑制胆管癌细胞株SK-ChA-1的增殖并诱导细胞凋亡。索拉非尼联合塞来昔布协同抑制胆管癌细胞株SK-ChA-1的增殖。塞来昔布使索拉非尼诱导的胆管癌细胞株SK-ChA-1的凋亡增加。结论索拉非尼联合塞来昔布能协同抑制胆管癌细胞株SK-ChA-1的增殖,这与塞来昔布使索拉非尼诱导的细胞凋亡增加有关。Objective To investigate the effect of sorafenib and celecoxib combination therapy on proliferation of hmnan cholangiocarcinoma （CC） ceils, using the cultured SK - ChA - 1 cell line. Methods Inhibition of SK - ChA - 1 cell proliferation by sorafenib alone and in combination with celecoxib was studied in vitro using the MTT assay. The anti - neoplastic mechanisms of sorafenib alone and in combination with celecoxib were assessed by Western blot detection of changes in the caspase cleavage substrate poly ADP - ribose polymerase （PARP）. Results SK - ChA - 1 cells treated with sorafenib alone showed a dose - dependent growth inhibition and degradation of PARP. Combination treatment with sorafenib and celecoxib synergistically increased the growth inhibition effects and enhanced the degradation of PARP. Conclusion Combination treatment with sorafenib and eelecoxib results in a synergistic anti - proliferative effect in the human CC cell line SK - ChA - 1 ; the addition of celecoxib enhances sorafenib - induced apoptosis.

关 键 词：胆管肿瘤 索拉非尼 塞来昔布 体外研究 

分 类 号：R735.8[医药卫生—肿瘤]